Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma.

Deshantri AK, Fens MH, Ruiter RWJ, Metselaar JM, Storm G, van Bloois L, Varela-Moreira A, Mandhane SN, Mutis T, Martens ACM, Groen RWJ, Schiffelers RM.

J Control Release. 2019 Feb 28;296:232-240. doi: 10.1016/j.jconrel.2019.01.028. Epub 2019 Jan 22.

PMID:
30682443
2.

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, de Bruijn JD, Ossenkoppele GJ, Zweegman S, Smit L, Mutis T, Martens ACM, van de Donk NWCJ, Groen RWJ.

Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6. No abstract available.

3.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
4.

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, Martens ACM, Zweegman S, van de Donk NWCJ, Groen RWJ, Lokhorst HM, Mutis T.

Mol Ther. 2017 Aug 2;25(8):1946-1958. doi: 10.1016/j.ymthe.2017.04.024. Epub 2017 May 13.

5.

Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.

Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, Lubbers-Aalders L, van Velzen JF, Bloem AC, Yuan H, de Bruijn JD, Ossenkoppele GJ, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Blood. 2016 Dec 22;128(25):2949-2959. doi: 10.1182/blood-2016-05-719021. Epub 2016 Oct 12.

6.

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

de Haart SJ, Holthof L, Noort WA, Minnema MC, Emmelot ME, Aarts-Riemens T, Doshi P, Sasser K, Yuan H, de Bruijn J, Martens AC, van de Donk NW, Lokhorst HM, Groen RW, Mutis T.

Haematologica. 2016 Aug;101(8):e339-42. doi: 10.3324/haematol.2015.139667. Epub 2016 May 5. No abstract available.

7.

Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.

Sontakke P, Carretta M, Jaques J, Brouwers-Vos AZ, Lubbers-Aalders L, Yuan H, de Bruijn JD, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Leukemia. 2016 Oct;30(10):2064-2073. doi: 10.1038/leu.2016.108. Epub 2016 Apr 29.

PMID:
27125308
8.

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T.

Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8.

9.

Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis.

van den Boom V, Maat H, Geugien M, Rodríguez López A, Sotoca AM, Jaques J, Brouwers-Vos AZ, Fusetti F, Groen RW, Yuan H, Martens AC, Stunnenberg HG, Vellenga E, Martens JH, Schuringa JJ.

Cell Rep. 2016 Jan 12;14(2):332-46. doi: 10.1016/j.celrep.2015.12.034. Epub 2015 Dec 31.

10.

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, Martens AC, Doshi P, Sasser K, Mutis T, van de Donk NW.

Leukemia. 2015 Oct;29(10):2039-49. doi: 10.1038/leu.2015.123. Epub 2015 May 15.

PMID:
25975191
11.

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.

Sarkar S, van Gelder M, Noort W, Xu Y, Rouschop KM, Groen R, Schouten HC, Tilanus MG, Germeraad WT, Martens AC, Bos GM, Wieten L.

Cancer Immunol Immunother. 2015 Aug;64(8):951-63. doi: 10.1007/s00262-015-1694-4. Epub 2015 Apr 29.

12.

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.

Overdijk MB, Verploegen S, Bögels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, Parren PW.

MAbs. 2015;7(2):311-21. doi: 10.1080/19420862.2015.1007813.

13.

Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.

Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M.

J Immunol. 2015 Feb 1;194(3):911-20. doi: 10.4049/jimmunol.1402346. Epub 2014 Dec 17.

14.

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.

Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, van Bueren JJ, Parren PW, Lokhorst HM, van de Donk NW, Martens AC, Mutis T.

Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14.

15.

Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.

Gaudichon J, Milano F, Cahu J, DaCosta L, Martens AC, Renoir JM, Sola B.

PLoS One. 2014 Sep 25;9(9):e107009. doi: 10.1371/journal.pone.0107009. eCollection 2014.

16.

Differential effects of nitrostyrene derivatives on myelopoiesis involve regulation of C/EBPα and p38MAPK activity.

Bartels M, Calgarotto AK, Martens AC, Maso V, da Silva SL, Bierings MB, de Souza Queiroz ML, Coffer PJ.

PLoS One. 2014 Mar 10;9(3):e90586. doi: 10.1371/journal.pone.0090586. eCollection 2014.

17.

Brief report: Autologous stem cell transplantation restores immune tolerance in experimental arthritis by renewal and modulation of the Teff cell compartment.

Delemarre EM, Roord ST, van den Broek T, Zonneveld-Huijssoon E, de Jager W, Rozemuller H, Martens AC, Broere F, Wulffraat NM, Glant TT, Prakken BJ, van Wijk F.

Arthritis Rheumatol. 2014 Feb;66(2):350-6. doi: 10.1002/art.38261.

18.

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Garcia-Gomez A, Quwaider D, Canavese M, Ocio EM, Tian Z, Blanco JF, Berger AJ, Ortiz-de-Solorzano C, Hernández-Iglesias T, Martens AC, Groen RW, Mateo-Urdiales J, Fraile S, Galarraga M, Chauhan D, San Miguel JF, Raje N, Garayoa M.

Clin Cancer Res. 2014 Mar 15;20(6):1542-54. doi: 10.1158/1078-0432.CCR-13-1657. Epub 2014 Jan 31.

19.

Mesenchymal stem cell therapy in proteoglycan induced arthritis.

Swart JF, de Roock S, Hofhuis FM, Rozemuller H, van den Broek T, Moerer P, Broere F, van Wijk F, Kuis W, Prakken BJ, Martens AC, Wulffraat NM.

Ann Rheum Dis. 2015 Apr;74(4):769-77. doi: 10.1136/annrheumdis-2013-204147. Epub 2014 Jan 6.

PMID:
24395558
20.

In vitro induction of alkaline phosphatase levels predicts in vivo bone forming capacity of human bone marrow stromal cells.

Prins HJ, Braat AK, Gawlitta D, Dhert WJ, Egan DA, Tijssen-Slump E, Yuan H, Coffer PJ, Rozemuller H, Martens AC.

Stem Cell Res. 2014 Mar;12(2):428-40. doi: 10.1016/j.scr.2013.12.001. Epub 2013 Dec 12.

21.

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, Yuan H, Groen RW, McMillin DW, Jakubikova J, Lokhorst HM, Martens AC, Mitsiades CS, Mutis T.

Clin Cancer Res. 2013 Oct 15;19(20):5591-601. doi: 10.1158/1078-0432.CCR-12-3676. Epub 2013 Sep 4.

22.

Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells.

Guichelaar T, Emmelot ME, Rozemuller H, Martini B, Groen RW, Storm G, Lokhorst HM, Martens AC, Mutis T.

Clin Cancer Res. 2013 Mar 15;19(6):1467-75. doi: 10.1158/1078-0432.CCR-12-2177. Epub 2013 Feb 4.

23.

Spatial distribution and survival of human and goat mesenchymal stromal cells on hydroxyapatite and β-tricalcium phosphate.

Prins HJ, Fernandes H, Rozemuller H, van Blitterswijk C, de Boer J, Martens AC.

J Tissue Eng Regen Med. 2016 Mar;10(3):233-44. doi: 10.1002/term.1681. Epub 2012 Dec 18.

PMID:
23255230
24.

The impact of cell source, culture methodology, culture location, and individual donors on gene expression profiles of bone marrow-derived and adipose-derived stromal cells.

Torensma R, Prins HJ, Schrama E, Verwiel ET, Martens AC, Roelofs H, Jansen BJ.

Stem Cells Dev. 2013 Apr 1;22(7):1086-96. doi: 10.1089/scd.2012.0384. Epub 2012 Dec 21.

25.

Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment.

Carrancio S, Romo C, Ramos T, Lopez-Holgado N, Muntion S, Prins HJ, Martens AC, Briñón JG, San Miguel JF, Del Cañizo MC, Sanchez-Guijo F.

Cell Transplant. 2013;22(7):1171-83. doi: 10.3727/096368912X657431. Epub 2012 Oct 2.

26.

Dll1+ secretory progenitor cells revert to stem cells upon crypt damage.

van Es JH, Sato T, van de Wetering M, Lyubimova A, Yee Nee AN, Gregorieff A, Sasaki N, Zeinstra L, van den Born M, Korving J, Martens ACM, Barker N, van Oudenaarden A, Clevers H.

Nat Cell Biol. 2012 Oct;14(10):1099-1104. doi: 10.1038/ncb2581. Epub 2012 Sep 23.

27.

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma.

Groen RW, Noort WA, Raymakers RA, Prins HJ, Aalders L, Hofhuis FM, Moerer P, van Velzen JF, Bloem AC, van Kessel B, Rozemuller H, van Binsbergen E, Buijs A, Yuan H, de Bruijn JD, de Weers M, Parren PW, Schuringa JJ, Lokhorst HM, Mutis T, Martens AC.

Blood. 2012 Jul 19;120(3):e9-e16. doi: 10.1182/blood-2012-03-414920. Epub 2012 May 31.

28.

Histological assessment of the sclerotic graft-versus-host response in the humanized RAG2-/-γc-/- mouse model.

Hogenes MC, van Dorp S, van Kuik J, Monteiro FR, ter Hoeve N, van Dijk MR, Martens AC, de Weger RA.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1023-35. doi: 10.1016/j.bbmt.2012.05.002. Epub 2012 May 9.

29.

Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation.

Noort WA, Oerlemans MI, Rozemuller H, Feyen D, Jaksani S, Stecher D, Naaijkens B, Martens AC, Bühring HJ, Doevendans PA, Sluijter JP.

J Cell Mol Med. 2012 Aug;16(8):1827-39. doi: 10.1111/j.1582-4934.2011.01455.x.

30.

Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.

Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PW, Medema RH, Martens AC, Brenkman AB, Voest EE.

Cancer Cell. 2011 Sep 13;20(3):370-83. doi: 10.1016/j.ccr.2011.08.010.

31.

N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.

Groen RW, de Rooij MF, Kocemba KA, Reijmers RM, de Haan-Kramer A, Overdijk MB, Aalders L, Rozemuller H, Martens AC, Bergsagel PL, Kersten MJ, Pals ST, Spaargaren M.

Haematologica. 2011 Nov;96(11):1653-61. doi: 10.3324/haematol.2010.038133. Epub 2011 Aug 9.

32.

Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen.

Spaapen RM, Groen RW, van den Oudenalder K, Guichelaar T, van Elk M, Aarts-Riemens T, Bloem AC, Storm G, Martens AC, Lokhorst HM, Mutis T.

Clin Cancer Res. 2010 Nov 15;16(22):5481-8. doi: 10.1158/1078-0432.CCR-10-1340. Epub 2010 Nov 9.

33.

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC.

Haematologica. 2010 Dec;95(12):2063-71. doi: 10.3324/haematol.2010.025783. Epub 2010 Sep 17.

34.

Luciferase labeling for multipotent stromal cell tracking in spinal fusion versus ectopic bone tissue engineering in mice and rats.

Geuze RE, Prins HJ, Öner FC, van der Helm YJ, Schuijff LS, Martens AC, Kruyt MC, Alblas J, Dhert WJ.

Tissue Eng Part A. 2010 Nov;16(11):3343-51. doi: 10.1089/ten.TEA.2009.0774. Epub 2010 Jul 13.

PMID:
20575656
35.

Prospective isolation of mesenchymal stem cells from multiple mammalian species using cross-reacting anti-human monoclonal antibodies.

Rozemuller H, Prins HJ, Naaijkens B, Staal J, Bühring HJ, Martens AC.

Stem Cells Dev. 2010 Dec;19(12):1911-21. doi: 10.1089/scd.2009.0510. Epub 2010 Aug 12.

PMID:
20367498
36.

Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.

Reijmers RM, Groen RW, Rozemuller H, Kuil A, de Haan-Kramer A, Csikós T, Martens AC, Spaargaren M, Pals ST.

Blood. 2010 Jan 21;115(3):601-4. doi: 10.1182/blood-2009-02-204396. Epub 2009 Nov 13.

37.

Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model.

Postnov AA, Rozemuller H, Verwey V, Lokhorst H, De Clerck N, Martens AC.

Calcif Tissue Int. 2009 Nov;85(5):434-43. doi: 10.1007/s00223-009-9284-0. Epub 2009 Oct 9.

38.

Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum.

Prins HJ, Rozemuller H, Vonk-Griffioen S, Verweij VG, Dhert WJ, Slaper-Cortenbach IC, Martens AC.

Tissue Eng Part A. 2009 Dec;15(12):3741-51. doi: 10.1089/ten.TEA.2008.0666.

PMID:
19519274
39.

In vivo matrix production by bone marrow stromal cells seeded on PLGA scaffolds for ligament tissue engineering.

van Eijk F, Saris DB, Fedorovich NE, Kruyt MC, Willems WJ, Verbout AJ, Martens AC, Dhert WJ, Creemers L.

Tissue Eng Part A. 2009 Oct;15(10):3109-17. doi: 10.1089/ten.TEA.2008.0541.

PMID:
19338450
40.

Non-invasive imaging of mouse hepatitis coronavirus infection reveals determinants of viral replication and spread in vivo.

Raaben M, Prins HJ, Martens AC, Rottier PJ, De Haan CA.

Cell Microbiol. 2009 May;11(5):825-41. doi: 10.1111/j.1462-5822.2009.01298.x. Epub 2009 Feb 10.

PMID:
19215224
41.

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.

Rozemuller H, van der Spek E, Bogers-Boer LH, Zwart MC, Verweij V, Emmelot M, Groen RW, Spaapen R, Bloem AC, Lokhorst HM, Mutis T, Martens AC.

Haematologica. 2008 Jul;93(7):1049-57. doi: 10.3324/haematol.12349. Epub 2008 May 19.

42.

In vivo bioluminescence imaging study to monitor ectopic bone formation by luciferase gene marked mesenchymal stem cells.

Olivo C, Alblas J, Verweij V, Van Zonneveld AJ, Dhert WJ, Martens AC.

J Orthop Res. 2008 Jul;26(7):901-9. doi: 10.1002/jor.20582.

43.

Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality.

van Rijn RS, Simonetti ER, Hagenbeek A, Bonyhadi M, Storm G, Martens AC, Ebeling SB.

Exp Hematol. 2007 Jan;35(1):117-27.

PMID:
17198880
44.

Continuity of care in the ambulatory treatment of adolescents with asthma.

Cyr MC, Martens AC, Berbiche D, Perreault S, Blais L.

J Adolesc Health. 2006 Dec;39(6):926.e11-7. Epub 2006 Sep 27.

PMID:
17116528
45.

Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes.

Rozemuller H, Knaän-Shanzer S, Hagenbeek A, van Bloois L, Storm G, Martens AC.

Exp Hematol. 2004 Nov;32(11):1118-25.

PMID:
15539091
46.

Genetic marking with the DeltaLNGFR-gene for tracing goat cells in bone tissue engineering.

Kruyt MC, Stijns MM, Fedorovich NE, De Bruijn JD, Van Blitterswijk CA, Verbout AJ, Rozemuller H, Hagenbeek A, Dhert WJ, Martens AC.

J Orthop Res. 2004 Jul;22(4):697-702.

47.

A P19Cl6 GFP reporter line to quantify cardiomyocyte differentiation of stem cells.

Moore JC, Spijker R, Martens AC, de Boer T, Rook MB, van der Heyden MA, Tertoolen LG, Mummery CL.

Int J Dev Biol. 2004 Feb;48(1):47-55.

48.

Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis.

Rookmaaker MB, Smits AM, Tolboom H, Van 't Wout K, Martens AC, Goldschmeding R, Joles JA, Van Zonneveld AJ, Gröne HJ, Rabelink TJ, Verhaar MC.

Am J Pathol. 2003 Aug;163(2):553-62.

49.

A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.

van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, Rijkers G, Martens AC, Ebeling SB.

Blood. 2003 Oct 1;102(7):2522-31. Epub 2003 Jun 5.

Supplemental Content

Loading ...
Support Center